PHILADELPHIA--(BUSINESS WIRE)--TransCelerate BioPharma Inc., today announced that Janice Chang, currently its Chief Operating Officer, has been appointed as TransCelerate’s new Chief Executive Officer. Janice will assume the role on January 1, 2023. TransCelerate is a collaborative organization dedicated to accelerating the development of new medicines and improving the health of people around the world.
“I am honored to be selected by our esteemed Board of Directors as the next CEO of TransCelerate. Under my leadership, we will work closely with our Member Company leaders around the globe to drive our mission forward. We are at a pivotal time in our industry and I’m inspired everyday by the passion I see across our R&D community to transform our ways of working to drive patient value. By engaging more deeply with stakeholders across the entire ecosystem, together, I’m confident we will accelerate transformation and solutions to bring innovative treatments to patients,” said Chang.
Janice, who joined TransCelerate in 2014, will succeed founding CEO Dalvir Gill, Ph.D., who announced his retirement after a long and successful career in drug development spanning over 30 years.
“After an extensive search, the Board of Directors agreed that Janice is the ideal candidate to lead TransCelerate. She has demonstrated outstanding leadership and made significant progress advancing TransCelerate’s mission. The Board is committed to providing Janice with our unwavering support as the head of this organization. The Board is extremely grateful to Dalvir as our first CEO, who in 10 years, has galvanized collaboration among 20 major biopharma companies, global regulators, and multiple other stakeholders around the world,” said Kate Owen, Chair of the Board of Directors at TransCelerate and Head, Global Development, Janssen Research & Development, LLC.
“It has been a privilege working with Janice these last few years,” said Dalvir. “In 2012, pharma leaders envisaged a future for biopharma collaboration that would address common challenges and inefficiencies in drug development. Today that vision is reality, and TransCelerate has played a major role in creating sustainable change in the drug development ecosystem. I am proud of what we have achieved thus far, and Janice is the perfect leader to continue that success and guide TransCelerate into the future.”
About TransCelerate BioPharma, Inc.
TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by accelerating and simplifying the research and development (R&D) of innovative new therapies. The organization’s mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design, and facilitate implementation of solutions intended to drive the efficient, effective, and high-quality delivery of new medicines. The vast majority of TransCelerate solutions are publicly available. Headquartered in Philadelphia, TransCelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety and, as appropriate, harmonizing process and sharing information.
Membership in TransCelerate is open to pharmaceutical and biotechnology companies with R&D operations. For more information, please visit http://www.transceleratebiopharmainc.com, https://twitter.com/TransCelerate, or https://www.linkedin.com/company/transcelerate-biopharma-inc-/.
